This is a historical report — it no longer reflects this drug's current status. Current status: Active Shortage. View this drug's full profile page →

Shortage Avoided

MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE

MYLAN PHARMACEUTICALS ULC

View this drug's full profile page →

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE in Canada?

Yes. MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 600MG 200MG 300MG has an active shortage reported to Health Canada (last updated April 14, 2025).

Why is MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE not available?

The reason the manufacturer reported: Disruption of the manufacture of the drug.

When will MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE be available again?

No estimated resolution date has been reported yet. Follow this page to get an email as soon as the status changes.

Can I still get this?Check with your pharmacist

StatusShortage Avoided

Same-ingredient products on fileNone found

Affected strength600MG 200MG 300MG

Last updated2020-07-09

What this means

Does this mean the shortage is completely over everywhere?

It means this specific report has been marked resolved or was avoided — but some individual pharmacies may still take time to restock.

What should I do?

If your pharmacy still doesn't have it, check with them directly — supply is expected to be normalizing.

DIN

02461412

Strength

600MG 200MG 300MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL FUMARATE

Tier

Unrated

Last Updated

2020-07-09

Reason for Shortage

Other (Please describe in comments)

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE has 2 shortage/discontinuation reports on file — this is one of them.

2025-04-14

Active Shortage

Disruption of the manufacture of the drug.

Other Products from MYLAN PHARMACEUTICALS ULC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

AZITHROMYCIN FOR INJECTION, USP

500MG · DIN 02385473

333MG · DIN 02293269

40MG · DIN 02257963

10MG · DIN 02257955

DIN 02388138

DIN 02388146